克里唑蒂尼
间变性淋巴瘤激酶
医学
肺癌
融合基因
碱性抑制剂
生长激素受体
酪氨酸激酶
内科学
癌症研究
酪氨酸激酶抑制剂
腺癌
肿瘤科
ROS1型
癌症
基因
受体
生物
激素
生长激素
恶性胸腔积液
生物化学
作者
Xue Pan,Anyuan Zhong,Yufei Xing,Xi Li,Haiwei Du,Minhua Shi
标识
DOI:10.1177/03000605211044652
摘要
Anaplastic lymphoma kinase ( ALK) rearrangement occurs in approximately 5% of non-small cell lung cancers (NSCLCS), and EML4-ALK is the most commonly observed ALK fusion variant in NSCLC. However, growth hormone receptor ( GHR) as the fusion partner for ALK and the clinical response to ALK tyrosine kinase inhibitors in patients with metastatic lung adenocarcinoma (LUAD) who carry the GHR-ALK variant have not been documented. This case describes a 63-year-old woman diagnosed with metastatic LUAD. Immunohistochemistry revealed positive ALK expression, and the patient was treated with crizotinib. After 3 weeks of treatment, the patient had a partial response. Because of treatment-related adverse events, the dose of crizotinib was reduced. After 3.7 months, computed tomography uncovered disease progression. Next-generation sequencing identified a novel GHR-ALK fusion in the plasma of the patient. The patient was treated again with crizotinib, but the disease progressed again 2 months later. Then, the patient received chemotherapy. She succumbed to her disease 11 months after the initial diagnosis. Our work provides evidence supporting the use of crizotinib in patients with metastatic LUAD harboring GHR-ALK.
科研通智能强力驱动
Strongly Powered by AbleSci AI